Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients
| Autor: | A. Patzak, Katja Fuecker, C. Köhler, Hannes Rietzsch, Sabine Fischer, Theodora Temelkova-Kurktschiev, J. Wildbrett, Markolf Hanefeld, Uta Schwanebeck |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Insulin sensitivity Type 2 Diabetes Mellitus Type 2 diabetes medicine.disease Placebo Glibenclamide Endocrinology Postprandial Internal medicine Internal Medicine medicine business medicine.drug Acarbose |
| Zdroj: | Diabetes, Obesity and Metabolism. 5:38-44 |
| ISSN: | 1462-8902 |
| DOI: | 10.1046/j.1463-1326.2003.00239.x |
| Popis: | Aim: The aim of our double-blind, placebo-controlled study was to compare the effect of acarbose and glibenclamide on the insulin sensitivity in type 2 diabetes. Methods: We investigated 77 patients (mean age 58.7 years, mean BMI 27.3 kg/m2), treated by diet alone for at least 4 weeks. The subjects were randomized into three treatment groups for 16 weeks: 100 mg t.i.d. acarbose (n = 25) or 1 mg t.i.d. glibenclamide (n = 27) or one t.i.d. placebo (n = 25). Before and after therapy, the levels of fasting plasma glucose, glycosylated haemoglobin, fasting insulin, plasma glucose and insulin 1 h after a standardized breakfast were measured and insulin sensitivity determined by euglycaemic hyperinsulinaemic clamp test. Results: After the treatment period, BMI in the acarbose and placebo group decreased significantly, whereas in the glibenclamide group a significant increase was observed. Fasting plasma glucose was only significant reduced under glibenclamide. The postprandial glucose decreased significantly after acarbose (13.8 vs. 11.4 mmol/l, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text